FDA Rejects Endo Petition To Protect Its Opana Painkiller

In a rebuff to Endo Health Solutions, the FDA has denied a citizen petition that the drugmaker had filed last year in an attempt to thwart generic competition to its Opana ER painkiller. The decision is a setback for the drugmaker because not only does it mean that generics will soon become available, but the FDA denial is also likely to diminish the value of its newer, reformulated Opana ER.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news